The goal of the partnership – the Critical Path for Rare Neurodegenerative Diseases (CP-RND) – is to generate ‘actionable solutions that can tangibly accelerate’ drug development for amyotrophic lateral sclerosis (ALS) and other rare neurodegenerative diseases, the FDA said in a statement.
Hilary Marston, FDA chief medical officer, said: « There is a crucial need to develop new treatments that can improve and extend the lives of people diagnosed with rare neurodegenerative diseases, including ALS. Collaboration across public and private sectors can accelerate the progress to address this urgent need.
“The partnership we are announcing will leverage the shared expertise of all participants to create a path towards new breakthroughs in treating these diseases.”…
